Third Point SPRY trades
Daniel Loeb
Daniel Loeb ARS Pharmaceuticals, Inc stake
total: 588
Trades details
- Total transactions:
- 2
- New positions:
- 1
- Added:
- 1
- Held since:
- 2025 Q4
- Held for:
- 3 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, Daniel Loeb holds 1,000,000 ARS Pharmaceuticals, Inc (SPRY) shares with a market value of roughly $8.01M accounting for 0.17% of the overall portfolio. To date, the estimated cost basis is nearly $10.04 for "buy" trades. Third Point first purchased SPRY in 2025 Q4, initially acquiring 556,237 shares. Since the initial investment in ARS Pharmaceuticals, Inc (SPRY), Third Point has made 1 more transaction.
When did Daniel Loeb buy ARS Pharmaceuticals, Inc (SPRY)?
Daniel Loeb first invested in ARS Pharmaceuticals, Inc (SPRY) in 2025 Q4 at the reported quarter-end price of $11.65 per share.
What's the cost basis of Third Point's SPRY stake?
The estimated cost basis for ARS Pharmaceuticals, Inc (SPRY) stake is around $10.04 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $10.04
Daniel Loeb's historical trades in ARS Pharmaceuticals, Inc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.39%
|
1,000,000
|
$8.03
|
$8,030,000
|
+79.78% (+443,763)
|
+0.17%
|
|
2025 Q4
|
0.09%
|
556,237
|
$11.65
|
$6,480,161
|
new
|
+0.09%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.